Shanghai Pharma reveals aggressive expansion plan

29 January 2018

Shanghai Pharma is set to expand to San Diego, USA, with a new R&D hub, and is also seeking to gain technology and market access “through the short-cut route of acquisitions,” chairman Zhou Jun told the South China Morning Post recently.

The interview reveals the firm’s ambitious plan to expand internationally, after it acquired the Chinese arm of Cardinal Health for about half a billion dollars.

Shanghai Pharma, which currently spends over $100 million on research and development annually, is focused on digestive, metabolic and cardiovascular diseases, among other therapeutic areas, and is listed in Hong Kong as well as Shanghai. It is about a third owned by local government.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK